| ［1］ |
Maurer M, Church MK, Gonçalo M, et al. Management and treatment of chronic urticaria （CU）［J］. J Eur Acad Dermatol Venereol, 2015,29 Suppl 3:16⁃32. doi: 10.1111/jdv.13198.
|
| ［2］ |
D′Amato G, Stanziola A, Sanduzzi A, et al. Treating severe allergic asthma with anti⁃IgE monoclonal antibody （omalizumab）: a review［J］. Multidiscip Respir Med, 2014,9（1）:23. doi: 10.1186/2049⁃6958⁃9⁃23.
|
| ［3］ |
Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria［J］. Ann Allergy Asthma Immunol, 2007,99（2）:190⁃193. doi: 10.1016/S1081⁃1206（10）60644⁃8.
|
| ［4］ |
Godse KV. Omalizumab in severe chronic urticaria［J］. Indian J Dermatol Venereol Leprol, 2008,74（2）:157⁃158.
|
| ［5］ |
Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know［J］. J Allergy Clin Immunol, 2017,139（6）:1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050.
|
| ［6］ |
Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab⁃induced reductions in mast cell FcεRI and function［J］. J Allergy Clin Immunol, 2004,114（3）:527⁃530. doi: 10.1016/j.jaci. 2004.06.032.
|
| ［7］ |
Hsu CL, Shiung YY, Lin BL, et al. Accumulated immune complexes of IgE and omalizumab trap allergens in an in vitro model［J］. Int Immunopharmacol, 2010,10（4）:533⁃539. doi: 10. 1016/j.intimp.2010.02.001.
|
| ［8］ |
Kalesnikoff J, Huber M, Lam V, et al. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival［J］. Immunity, 2001,14（6）:801⁃811.
|
| ［9］ |
Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2015,135（2）:337⁃342. doi: 10.1016/j.jaci.2014.04.036.
|
| ［10］ |
Chan MA, Gigliotti NM, Dotson AL, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells［J］. Clin Transl Allergy, 2013,3（1）:29. doi: 10.1186/2045⁃7022⁃3⁃29.
|
| ［11］ |
Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo⁃controlled, dose⁃ranging study of single⁃dose omalizumab in patients with H1⁃antihistamine⁃refractory chronic idiopathic urticaria［J］. J Allergy Clin Immunol, 2011,128（3）:567⁃573.e1. doi: 10.1016/j.jaci.2011.06.010.
|
| ［12］ |
Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2017,139（3）:1059⁃1061.e1. doi: 10.1016/j.jaci.2016.07.047.
|
| ［13］ |
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and Update［J］. Allergy, 2018. doi: 10.1111/all.13397.
|
| ［14］ |
Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab⁃discontinued chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2017,140（6）:1749⁃1751. doi: 10.1016/j.jaci.2017.08.007.
|
| ［15］ |
Fine LM, Bernstein JA. Urticaria guidelines: consensus and controversies in the European and American guidelines［J］. Curr Allergy Asthma Rep, 2015,15（6）:30. doi: 10.1007/s11882⁃015⁃0535⁃z.
|
| ［16］ |
McCormack PL. Omalizumab: a review of its use in patients with chronic spontaneous urticaria［J］. Drugs, 2014,74（14）:1693⁃1699. doi: 10.1007/s40265⁃014⁃0290⁃9.
|
| ［17］ |
Labrador⁃Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticaria［J］. Drug Des Devel Ther, 2015,9:4909⁃4915. doi: 10.2147/DDDT.S56004.
|
| ［18］ |
Saini SS, Bindslev⁃Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo⁃controlled study［J］. J Invest Dermatol, 2015,135（1）:67⁃75. doi: 10.1038/jid.2014.306.
|
| ［19］ |
Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria［J］. N Engl J Med, 2013,368（10）:924⁃935. doi: 10.1056/NEJMoa1215372.
|
| ［20］ |
Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy［J］. J Allergy Clin Immunol, 2013,132（1）:101⁃109. doi: 10.1016/j.jaci.2013.05.013.
|
| ［21］ |
Casale TB, Bernstein JA, Maurer M, et al. Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy［J］. J Allergy Clin Immunol Pract, 2015,3（5）:743⁃750.e1. doi: 10.1016/j.jaip.2015.04.015.
|
| ［22］ |
Giménez⁃Arnau AM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety［J］. Expert Opin Biol Ther, 2017,17（3）:375⁃385. doi: 10.1080/14712598.2017. 1285 903.
|
| ［23］ |
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti⁃IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma［J］. J Allergy Clin Immunol, 2001,108（2）:184⁃190. doi: 10.1067/mai.2001.117880.
|
| ［24］ |
Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials［J］. J Allergy Clin Immunol, 2016,137（6）:1742⁃1750.e4. doi: 10.1016/j.jaci.2015.12.1342.
|
| ［25］ |
Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence［J］. J Allergy Clin Immunol, 2018,141（2）:638⁃649. doi: 10.1016/j.jaci.2017.06.032.
|
